Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Research output: Contribution to journal › Journal article › Research › peer-review
Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L.Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.
Original language | English |
---|---|
Journal | Haematologica |
Volume | 87 |
Issue number | 3 |
Pages (from-to) | 322-3 |
Number of pages | 1 |
ISSN | 0390-6078 |
Publication status | Published - 2002 |
Bibliographical note
Keywords: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin, Recombinant; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome
ID: 8463466